After failing to pass in the previous Congress, a revised version of the “BIOSECURE Act” (“the Act”) was signed into law by President Trump on December 18, 2025, as Section 851 of the National Defense Authorization Act (“NDAA”) for Fiscal Year 2026 (P.L. 119-60). The new law will restrict US federal procurement and grants involving biotechnology products or services provided by “biotechnology companies of concern” (“BCC”). While amended and clarified in key areas, the Act…
Bipartisan legislation advancing in the U.S. Senate and the U.S. House of Representatives known as the “BIOSECURE Act” (“the Act”) has the potential to restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the U.S. government. Following the same model that was used to target Chinese telecommunications companies in the late 2010s, the Act would prohibit federal “executive agencies” from contracting with or extending loans…
